A Statement of the MDS on Biological Definition, Staging, and Classification of Parkinson's Disease

Francisco Cardoso¹, Christopher G Goetz², Tiago A Mestre³, Cristina Sampaio^{4

5}, Charles H Adler⁶, Daniela Berg⁷, Bastiaan R Bloem⁸, David J Burn⁹, Michael S Fitts¹⁰, Thomas Gasser¹¹, Christine Klein¹², Marina A J de Tijssen¹³, Anthony E Lang¹⁴, Shen-Yang Lim¹⁵, Irene Litvan¹⁶, Wassilios G Meissner^{17

18

19}, Brit Mollenhauer²⁰, Njideka Okubadejo²¹, Michael S Okun²², Ronald B Postuma²³, Per Svenningsson²⁴, Louis C S Tan²⁵, Taiji Tsunemi²⁶, Sarah Wahlstrom-Helgren²⁷, Oscar S Gershanik^{28

29}, Victor S C Fung³⁰, Claudia Trenkwalder^{31

32}

Affiliations

¹ Movement Disorders Unit, Neurology Service, Internal Medicine Department, The Federal University of Minas Gerais, Belo Horizonte, Brazil.
² Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.
³ Ottawa Hospital Research Institute; University of Ottawa Brain and Mind Research Institute; Division of Neurology, Department of Medicine, University of Ottawa, The Ottawa Hospital Ottawa, Ottawa, Ontario, Canada.
⁴ CHDI Management/CHDI Foundation, Princeton, New Jersey, USA.
⁵ Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Lisbon, Portugal.
⁶ Department of Neurology, Mayo Clinic College of Medicine, Mayo Clinic Arizona, Phoenix, Arizona, USA.
⁷ Department of Neurology, University Hospital Schleswig-Holstein, Campus Kiel and Christian Albrechts-University of Kiel, Kiel, Germany.
⁸ Radboud University Medical Center, Donders Institute for Brain, Cognition, and Behavior, Department of Neurology, Center of Expertise for Parkinson and Movement Disorders, Nijmegen, The Netherlands.
⁹ Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.
¹⁰ UAB Libraries, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
¹¹ Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany. German Center for Neurodegenerative Diseases, Tübingen, Germany.
¹² Institute of Neurogenetics, University of Lübeck, Lübeck, Germany.
¹³ Department of Neurology, Expertise Centre Movement Disorders, University Medical Centre Groningen, Groningen, The Netherlands.
¹⁴ Edmond J. Safra Program in Parkinson's Disease, University Health Network and the University of Toronto, Toronto, Ontario, Canada.
¹⁵ Division of Neurology, Department of Medicine, and the Mah Pooi Soo and Tan Chin Nam Centre for Parkinson's and Related Disorders, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
¹⁶ Parkinson and Other Movement Disorders Center, Department of Neurosciences, University of California San Diego, La Jolla, California, USA.
¹⁷ CHU Bordeaux, Service de Neurologie des Maladies Neurodégénératives, Bordeaux, France.
¹⁸ Univ. Bordeaux, CNRS, IMN, Bordeaux, France.
¹⁹ Department of Medicine, University of Otago, Christchurch, and New Zealand Brain Research Institute, Christchurch, New Zealand.
²⁰ Department of Neurology, University Medical Center, Kassel, Germany.
²¹ Neurology Unit, Department of Medicine, Faculty of Clinical Sciences, College of Medicine, University of Lagos, Lagos, Nigeria.
²² Adelaide Lackner Professor of Neurology, Norman Fixel Institute for Neurological Diseases, University of Florida Health, Gainsville, Florida, USA.
²³ Department of Neurology, McGill University, Montreal Neurological Institute, Montreal, Quebec, Canada.
²⁴ Section of Neurology, Karolinska Institutet, Stockholm, Sweden.
²⁵ National Neuroscience Institute, Singapore.
²⁶ Department of Neurology, Juntendo University Faculty of Medicine, Tokyo, Japan.
²⁷ International Parkinson and Movement Disorder Society, Milwaukee, Wisconsin, USA.
²⁸ Movement Disorders Unit, Institute of Neuroscience, Favaloro Foundation University Hospital, Buenos Aires, Argentina.
²⁹ Cognitive Neuroscience Laboratory, Institute of Cognitive Neurology (INECO), Buenos Aires, Argentina.
³⁰ Movement Disorders Unit, Department of Neurology, Westmead Hospital and Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
³¹ Paracelsus-Elena Klinik, Kassel, Germany.
³² Department of Neurosurgery, University Medical Center, Goettingen, Germany.

PMID: 38093469
DOI: 10.1002/mds.29683

A Statement of the MDS on Biological Definition, Staging, and Classification of Parkinson's Disease

Francisco Cardoso et al. Mov Disord. 2024 Feb.

. 2024 Feb;39(2):259-266.

doi: 10.1002/mds.29683. Epub 2023 Dec 13.

Authors

Affiliations

¹ Movement Disorders Unit, Neurology Service, Internal Medicine Department, The Federal University of Minas Gerais, Belo Horizonte, Brazil.
² Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.
³ Ottawa Hospital Research Institute; University of Ottawa Brain and Mind Research Institute; Division of Neurology, Department of Medicine, University of Ottawa, The Ottawa Hospital Ottawa, Ottawa, Ontario, Canada.
⁴ CHDI Management/CHDI Foundation, Princeton, New Jersey, USA.
⁵ Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Lisbon, Portugal.
⁶ Department of Neurology, Mayo Clinic College of Medicine, Mayo Clinic Arizona, Phoenix, Arizona, USA.
⁷ Department of Neurology, University Hospital Schleswig-Holstein, Campus Kiel and Christian Albrechts-University of Kiel, Kiel, Germany.
⁸ Radboud University Medical Center, Donders Institute for Brain, Cognition, and Behavior, Department of Neurology, Center of Expertise for Parkinson and Movement Disorders, Nijmegen, The Netherlands.
⁹ Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.
¹⁰ UAB Libraries, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
¹¹ Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany. German Center for Neurodegenerative Diseases, Tübingen, Germany.
¹² Institute of Neurogenetics, University of Lübeck, Lübeck, Germany.
¹³ Department of Neurology, Expertise Centre Movement Disorders, University Medical Centre Groningen, Groningen, The Netherlands.
¹⁴ Edmond J. Safra Program in Parkinson's Disease, University Health Network and the University of Toronto, Toronto, Ontario, Canada.
¹⁵ Division of Neurology, Department of Medicine, and the Mah Pooi Soo and Tan Chin Nam Centre for Parkinson's and Related Disorders, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
¹⁶ Parkinson and Other Movement Disorders Center, Department of Neurosciences, University of California San Diego, La Jolla, California, USA.
¹⁷ CHU Bordeaux, Service de Neurologie des Maladies Neurodégénératives, Bordeaux, France.
¹⁸ Univ. Bordeaux, CNRS, IMN, Bordeaux, France.
¹⁹ Department of Medicine, University of Otago, Christchurch, and New Zealand Brain Research Institute, Christchurch, New Zealand.
²⁰ Department of Neurology, University Medical Center, Kassel, Germany.
²¹ Neurology Unit, Department of Medicine, Faculty of Clinical Sciences, College of Medicine, University of Lagos, Lagos, Nigeria.
²² Adelaide Lackner Professor of Neurology, Norman Fixel Institute for Neurological Diseases, University of Florida Health, Gainsville, Florida, USA.
²³ Department of Neurology, McGill University, Montreal Neurological Institute, Montreal, Quebec, Canada.
²⁴ Section of Neurology, Karolinska Institutet, Stockholm, Sweden.
²⁵ National Neuroscience Institute, Singapore.
²⁶ Department of Neurology, Juntendo University Faculty of Medicine, Tokyo, Japan.
²⁷ International Parkinson and Movement Disorder Society, Milwaukee, Wisconsin, USA.
²⁸ Movement Disorders Unit, Institute of Neuroscience, Favaloro Foundation University Hospital, Buenos Aires, Argentina.
²⁹ Cognitive Neuroscience Laboratory, Institute of Cognitive Neurology (INECO), Buenos Aires, Argentina.
³⁰ Movement Disorders Unit, Department of Neurology, Westmead Hospital and Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
³¹ Paracelsus-Elena Klinik, Kassel, Germany.
³² Department of Neurosurgery, University Medical Center, Goettingen, Germany.

PMID: 38093469
DOI: 10.1002/mds.29683

No abstract available

Keywords: Parkinson's disease; diagnosis; parkinsonism; staging; α-synuclein.

PubMed Disclaimer

References

1. Dukes CE. The classification of cancer of the rectum. J Pathol Bacteriol 1932;35(3):323-332.
1. Greene FL, Sobin LH. The staging of cancer: a retrospective and prospective appraisal. CA Cancer J Clin 2008;58(3):180-190.
1. Ammar KA, Jacobsen SJ, Mahoney DW, et al. Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community. Circulation 2007;115(12):1563-1570.
1. Severino P, Mather PJ, Pucci M, et al. Advanced heart failure and end-stage heart failure: does a difference exist. Diagnostics (Basel) 2019;9(4):170.
1. Bueter A. On illness, disease, and priority: a framework for more fruitful debates. Med Health Care Philos 2019;22(3):463-474.

MeSH terms

Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

A Statement of the MDS on Biological Definition, Staging, and Classification of Parkinson's Disease

Affiliations

A Statement of the MDS on Biological Definition, Staging, and Classification of Parkinson's Disease

Authors

Affiliations

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous